Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Safety and Efficacy of BIO-101 175 mg b.i.d. and 350 mg b.i.d. 26-week Oral Administration to Patients Suffering From Age-related SARcopenia, Including Sarcopenic Obesity, Aged ≥65 Years and at Risk of Mobility Disability
Authors not listed
Biophytis · 2017
Abstract
The main objective of the study is to evaluate the effect of two daily doses of BIO101 versus placebo on mobility function as measured by gait speed using the 400MW test. The absolute change from baseline in meters/second observed in each treatment group at 6 Month was compared to the placebo group. Due to the Covid pandemic \>50% of data at endpoint was missing, which may have affected the ability of the study to deliver the expected results. Additionally, although the planned duration of treatment was 6 months, it was extended up to 9 months for some participants as a result of the pandemic.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-30 MST
Cite this
APA
Anonymous. (2017). Safety and Efficacy of BIO-101 175 mg b.i.d. and 350 mg b.i.d. 26-week Oral Administration to Patients Suffering From Age-related SARcopenia, Including Sarcopenic Obesity, Aged ≥65 Years and at Risk of Mobility Disability. <em>Biophytis</em>. https://clinicaltrials.gov/study/NCT03452488
Vancouver
Anonymous. Safety and Efficacy of BIO-101 175 mg b.i.d. and 350 mg b.i.d. 26-week Oral Administration to Patients Suffering From Age-related SARcopenia, Including Sarcopenic Obesity, Aged ≥65 Years and at Risk of Mobility Disability. Biophytis. 2017.
BibTeX
@misc{anon2017Safety,
title = {Safety and Efficacy of BIO-101 175 mg b.i.d. and 350 mg b.i.d. 26-week Oral Administration to Patients Suffering From Age-related SARcopenia, Including Sarcopenic Obesity, Aged ≥65 Years and at Risk of Mobility Disability},
author = {Anonymous},
journal = {Biophytis},
year = {2017},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Sara Espinoza 2017
Open access · US-GOV
The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity
Nature Reviews Endocrinology 2018
Preprint · OA
Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Hospital Universitario Ramon y Cajal 2021
Open access · US-GOV
MOVIhNG Study: Impact of a Personalized Multicomponent Exercise Program in Real Conditions on Physical Function, Frailty, and Quality of Life Among Older Adults With HIV
Astavita, Inc. 2015
Open access · US-GOV
Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Impact of a Daily Dose of an Astaxanthin Formulation Alone and With Exercise Training on Skeletal Muscle Function in the Elderly
Yuxiang Liang 2017
Open access · US-GOV
Effect of Balance Training on Mobility and Activities of Daily Living in Sarcopenic Inpatients Aged 80+Years
University of Arkansas 2009
Open access · US-GOV